Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) FCF Margin (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed FCF Margin for 10 consecutive years, with 48.13% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 14.0% to 48.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 69.99% through Dec 2025, up 519.0% year-over-year, with the annual reading at 69.99% for FY2025, 519.0% up from the prior year.
  • FCF Margin for Q4 2025 was 48.13% at Ultragenyx Pharmaceutical, up from 59.69% in the prior quarter.
  • The five-year high for FCF Margin was 48.13% in Q4 2025, with the low at 187.28% in Q1 2022.
  • Average FCF Margin over 5 years is 106.54%, with a median of 93.98% recorded in 2021.
  • Peak annual rise in FCF Margin hit 12405bps in 2021, while the deepest fall reached -23316bps in 2021.
  • Over 5 years, FCF Margin stood at 84.41% in 2021, then crashed by -34bps to 113.51% in 2022, then soared by 41bps to 67.19% in 2023, then increased by 28bps to 48.27% in 2024, then grew by 0bps to 48.13% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 48.13%, 59.69%, and 64.7% for Q4 2025, Q3 2025, and Q2 2025 respectively.